AzTrials
AzTrials

Mild Cognitive ImpairmentThinkingFitNCT01603862

ThinkingFit: Combined Physical, Cognitive and Social Treatment in Mild Cognitive Impairment (MCI)

A study testing ThinkingFit programme in people with Mild Cognitive Impairment, run by Dr Thomas Dannhauser at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Dementia is serious problem and around 700 000 people are affected in the UK alone. Currently there is no cure however early diagnosis and effective treatment offers hope for reducing the impact. Read more about this study

Who is it for?
Ages 40 years and older
Conditions the study is for
Mild Cognitive Impairment
What is being tested?
ThinkingFit programme
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
128 participants
Where
1 siteUnited Kingdom
Study dates
Jan 2010to Nov 2012
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients fulfilling criteria for AMCI [Petersen et al. 2001b]:
  • Memory impairment for age and education ii. No impairment in other cognitive domains iii. Normal social activities iv. Patient is not demented
  • For the other subtypes of MCI, cognitive impairment in one or more nonmemory domain
  • Sedentary lifestyle with no regular participation in physical exercise defined as two or three times a week for at least 20 minutes duration, or participation in active sport more than once a week, in the previous six months.
  • Willing and able to give informed consent.
  • Availability and access to safe exercise environments, such as paths or roads with sidewalks for walking or cycling.
  • At low risk from serious adverse effects from increased physical activity as indicated by performance on the revised Physical activity readiness questionnaire (PARQ).

Who cannot join

  • Type 1 (insulin dependent) diabetes mellitus.
  • Blood pressure of 160/100 mmHg or more.
  • Body weight more than 140% of ideal body weight.
  • Musculoskeletal or other medical problems preventing safe participation in regular moderate intensity exercise (65-77% of predicted maximum heart rate). This will include a resting tachycardia (heart rate above 100 bpm) and history of myocardial infarction or unstable angina within the last month.
  • Participants with modifiable exclusion criteria will be reconsidered after successful management. Patients will be referred for medical treatment prior to commencing exercise if indicated by the PARQ and the intervention will be guided by the PARmedX.
  • Participants taking medications affecting heart rate will need to be on a stable dosing regime for 3 months prior to commencing in order to control for potential spurious results on fitness measures caused by these treatments.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • North Essex Partnership Foundation NHS Trust

    Harlow, Essex, cm20 1qx

Other trials in United Kingdom

About this study

Official title: Piloting a Complex Intervention Involving Physical Exercise, Cognitive Training and Socialising to Delay the Onset of Dementia in Mild Cognitive Impairment

Dementia is serious problem and around 700 000 people are affected in the UK alone. Currently there is no cure however early diagnosis and effective treatment offers hope for reducing the impact. Dementia sufferers require care due to physical disability, cognitive deficits, social isolation and emotional symptoms (depression). Delaying the onset of dementia will improve quality of life for patients and reduce the cost of residential care (£42 000 per person per year).

People with mild cognitive impairment (MCI) are at high risk of developing dementia. They have impaired cognitive abilities, such as memory, but still manage their everyday activities. Studies show that 8 out of 10 people with MCI will have developed dementia 6 years after diagnosis.

Regular physical activities and performing a variety of cognitive activities reduce the risk of dementia and improves abilities and quality of life in healthy people. Therefore a combination of these activities may reduce the risk of developing dementia in MCI. The investigators want to see if they can develop a program which combines these activities in a fun and social way that gets people active and keeps them active. The aims are to improve fitness, cognition and quality of life. The investigators plan to use computers and the internet to help with the activities and to make them available to people who are isolated. Physical activity will involve walking from home, cognitive activities will be computer based games and puzzles and socialising will involve regular varied group-based activities. Participants (128) will be recruited from the UCL Derwent Memory Clinic and will complete a 26 week program. They will then be followed up yearly to monitor their progress. The main outcome of the study is engagement in the activities. The investigators will also measure fitness, cognition, quality of life and conversion to dementia.

Being tested
ThinkingFit programme
Medical subject headings
Cognitive Dysfunction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ThinkingFit programmeProcedure or surgery

    Combined physical, cognitive and social stimulation activties.

Study groups in NCT01603862
Study groupRoleWhat they receive
ThinkingFitExperimentalNot described
Receives: Procedure: ThinkingFit programme

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Activity Compliance

    Number of participants to have completed 50% or more of the programmed activity sessions during the intervention period.

    Measured: Compliance with programmed activities will be assessed at the end of participation which is expected to be at 24 weeks

Secondary outcomes (3)
  1. Cardiovascular fitness measure

    Cardiovascular fitness will be measured with a modified Siconolfi Step Test.

    Measured: This will be measured at the start, after the control period (12 weeks) and after completion of the activity interventions at around 24 weeks.

  2. Cognitive measures

    Participants will complete the following cognitive measures:

    • Visual and auditory divided attention task
    • Verbal episodic encoding and recognition task
    • Halstead Trail Making test (TMT)
    • Verbal fluency
    • Working memory tests: digit span forwards/ backwards

    Measured: This will be measured at the start, after the control period (12 weeks) and after completion of the activity interventions at around 24 weeks.

  3. Measures of quality of life and everyday activities

    Quality of life will be measured on the World Health Organization Quality of Life (WHOQOL) - BREF and change in every day activities on the Alzheimer's Disease Cooperative Study MCI Activities of Daily Living Scale (ADCS-MCI-ADL)

    Measured: This will be measured at the start, after the control period (12 weeks) and after completion of the activity interventions at around 24 weeks.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 May 2012 (estimated)
  2. Study startJan 2010
  3. Primary completionNov 2012
  4. Study completionNov 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
128 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01603862
Sponsor's protocol ID
ThinkingFit 1
Acronym
ThinkingFit
Status last verified
Apr 2014
First submitted
17 May 2012
Last updated
28 Apr 2014
Results posted
No
Data monitoring committee
Yes

Publications

  • Dannhauser TM, Cleverley M, Whitfield TJ, Fletcher BC, Stevens T, Walker Z. A complex multimodal activity intervention to reduce the risk of dementia in mild cognitive impairment--ThinkingFit: pilot and feasibility study for a randomized controlled trial. BMC Psychiatry. 2014 May 5;14:129. doi: 10.1186/1471-244X-14-129.

    PubMed 24886353

Questions about this trial

What is this clinical trial studying?

A study testing ThinkingFit programme in people with Mild Cognitive Impairment, run by Dr Thomas Dannhauser at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Activity Compliance (time frame: Compliance with programmed activities will be assessed at the end of participation which is expected to be at 24 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01603862, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in